Promoted from Head of North America
PITTSBURGH, Oct. 2 /CNW/ -- Mylan Inc. (NYSE: MYL) today announced the
appointment of Heather Bresch as Chief Operating Officer. Ms. Bresch served
previously as Head of North America and Chief Integration Officer. As Chief
Operation Officer, Ms. Bresch will be responsible for Mylan's global
commercial and technical operations, strategic planning, business development
and international affairs, which includes development of Mylan's
antiretroviral (ARV) franchise. She will also continue to oversee the
integration of Mylan's recent acquisition of Merck Generics.
Ms. Bresch has spent fifteen years with Mylan in various positions of
increasing responsibility throughout the company. Most recently, as Head of
North America, she had responsibility for Mylan's operations including Mylan
Pharmaceuticals, Mylan Technologies, and UDL Laboratories. Prior to this, she
served as Senior Vice President of Strategic Development in the Office of the
In her role as Chief Integration Officer, in addition to leading the
integration team working with Merck Generics, Ms. Bresch has overseen the
successful integration of Matrix Laboratories, in which Mylan took a
controlling stake earlier this year.
Ms. Bresch has been the only non-CEO to serve as Chairman of the Generic
Pharmaceutical Association (GPhA), serving an unprecedented two consecutive
terms, and is widely acknowledged in the industry for playing a critical role
in the passage of the 2003 Medicare Modernization Act, a Congressional
revision to the Hatch-Waxman Act of 1984 that focused on ensuring consumers'
access to affordable pharmaceuticals.
Mylan's Vice Chairman and CEO Robert J. Coury commented: "At this stage
in Mylan's history, it is imperative that we have a Chief Operating Officer in
place that knows our company, is a leader in the industry and has the
experience and energy required to execute on the opportunities of the new
Mylan. Heather is uniquely qualified for this challenging position, given her
in-depth knowledge of Mylan, Matrix and Merck Generics and her strong
relationships with management and employees across those organizations as a
result of leading the integration efforts. She has played an instrumental
role in Mylan's strategic development over the last several years, and will
continue be a key driver of the Company's future success."
Ms. Bresch earned an MBA and an undergraduate degree in international
studies and political science from West Virginia University.
Mylan Inc. is one of the world's leading quality generic and specialty
pharmaceutical companies. The Company offers one of the industry's broadest
and highest quality product portfolios, a robust product pipeline and a global
commercial footprint through operations in more than 90 countries. Through
its controlling interest in Matrix Laboratories Limited, Mylan has direct
access to one of the largest active pharmaceutical ingredient (API)
manufacturers in the world. Dey L.P., Mylan's fully integrated specialty
business, provides the Company with innovative and diversified opportunities
in the respiratory and allergy therapeutic areas.
For more information about Mylan, please visit www.mylan.com.
For further information:
For further information: Kris King, Mylan Inc., +1-724-514-1800 Web